87 related articles for article (PubMed ID: 33526351)
1. Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: A post-marketing surveillance.
Nakamura N; Kashitani Y; Yoshisue H; Nagasaki M; Sasajima T
Allergol Int; 2021 Jul; 70(3):319-326. PubMed ID: 33526351
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis.
Lai T; Wang S; Xu Z; Zhang C; Zhao Y; Hu Y; Cao C; Ying S; Chen Z; Li W; Wu B; Shen H
Sci Rep; 2015 Feb; 5():8191. PubMed ID: 25645133
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness.
Pelaia C; Calabrese C; Terracciano R; de Blasio F; Vatrella A; Pelaia G
Ther Adv Respir Dis; 2018; 12():1753466618810192. PubMed ID: 30400762
[TBL] [Abstract][Full Text] [Related]
4. [Adverse events in biologics for severe asthma].
Dargentolle G; Georges M; Beltramo G; Poisson C; Bonniaud P
Rev Mal Respir; 2024 May; 41(5):372-381. PubMed ID: 38653607
[TBL] [Abstract][Full Text] [Related]
5. Improvement of exertional dyspneoa in patients with chronic obstructive pulmonary disease and severe allergic asthma responding to omalizumab.
Pereira S; Verhille J; Cailliau E; Bonniaud P; Devouassoux G; Fry S; Guilleminault L; Khayath N; Leroyer C; Chenivesse C; Bautin N
Clin Exp Allergy; 2023 Dec; 53(12):1298-1301. PubMed ID: 37705326
[No Abstract] [Full Text] [Related]
6. Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA - an observational, 2 phase, patient reported outcomes study.
Canonica GW; Bartezaghi M; Marino R; Rigoni L
Clin Mol Allergy; 2015; 13(1):10. PubMed ID: 26155196
[TBL] [Abstract][Full Text] [Related]
7. Biological Drugs for the Treatment of Uncontrolled Severe Asthma in Children.
Indolfi C; Klain A; Bencivenga CL; D'Addio E; Dinardo G; Decimo A; Del Giudice MM
Curr Pediatr Rev; 2024; 20(3):265-270. PubMed ID: 37702164
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of the adoption of omalizumab in the treatment of pediatric allergic diseases.
Xu B; Tang L; Huang W; Xie S; Ye J; Luo G
Heliyon; 2024 Apr; 10(8):e29365. PubMed ID: 38681537
[TBL] [Abstract][Full Text] [Related]
9. Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan.
Shinozaki S; Watanabe A; Kimata M; Miyazaki M; Maekawa S
Infect Dis Ther; 2024 Jan; 13(1):189-205. PubMed ID: 38233606
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab: Practical considerations regarding the risk of anaphylaxis.
Kim HL; Leigh R; Becker A
Allergy Asthma Clin Immunol; 2010 Dec; 6(1):32. PubMed ID: 21129189
[TBL] [Abstract][Full Text] [Related]
11. Safety of sarilumab in a Japanese population with rheumatoid arthritis by age group: Data from an interim analysis of a post-marketing surveillance study.
Kameda H; Tasaka S; Takahashi T; Suzuki K; Soeda N; van Hoogstraten H; Diab R; Tanaka Y
Mod Rheumatol; 2024 May; ():. PubMed ID: 38804962
[TBL] [Abstract][Full Text] [Related]
12. Phase IV of Drug Development.
Suvarna V
Perspect Clin Res; 2010 Apr; 1(2):57-60. PubMed ID: 21829783
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy.
Meucci E; Radice A; Fassio F; Iorno MLC; Macchia D
Clin Case Rep; 2021 Oct; 9(10):e04935. PubMed ID: 34721849
[TBL] [Abstract][Full Text] [Related]
14. CORRIGENDUM: Safety and Effectiveness of Apixaban in Japanese Patients With Venous Thromboembolism in Clinical Practice - A Post-Marketing Surveillance.
Yamada N; Mo M; Ohsawa A; Sato M; Umeyama M; Shima D; Nakamura M
Circ J; 2024; 88(2):263. PubMed ID: 38267050
[No Abstract] [Full Text] [Related]
15. Child opportunity and outcomes in pediatric critical asthma: A multicenter analysis.
Gabbay JM; Mayourian J; Bajaj BVM; Wu AC; Graham RJ; Perez JM
J Allergy Clin Immunol Pract; 2024 May; ():. PubMed ID: 38703821
[No Abstract] [Full Text] [Related]
16. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.
Nieto García A; Garriga-Baraut T; Plaza Martín AM; Nieto Cid M; Torres Borrego J; Folqué Giménez MDM; Lozano Blasco J; Bosque García M; Moreno-Galarraga L; Tortajada-Girbés M; Rivas Juesas C; Penín Antón M; Caballero-Rabasco MA; Gaboli M; López Neyra A; Navarro Morón J; Freixa Benavente A; Valdesoiro Navarrete L; Ballester Asensio E; Sanz Santiago V; Romero García R; Gimeno Díaz de Atauri Á; Valenzuela Soria A; Sánchez Mateos M; Batlles Garrido J; Andrés Martín A; Campos Alonso E; Aragón Fernández C; Vázquez Rodríguez E; Martínez Pardo L; Del-Río Camacho G; Mazón Ramos Á
Pediatr Allergy Immunol; 2021 Jul; 32(5):980-991. PubMed ID: 33619748
[TBL] [Abstract][Full Text] [Related]
17. Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry.
Thomas D; Harvey ES; McDonald VM; Stevens S; Upham JW; Katelaris CH; Kritikos V; Gillman A; Harrington J; Hew M; Bardin P; Peters M; Reynolds PN; Langton D; Baraket M; Bowden JJ; Bowler S; Chien J; Chung LP; Farah CS; Grainge C; Jenkins C; Katsoulotos GP; Lee J; Radhakrishna N; Reddel HK; Rimmer J; Sivakumaran P; Wark PAB; Gibson PG
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2715-2724.e5. PubMed ID: 33545399
[TBL] [Abstract][Full Text] [Related]
18. Severe asthma: adding new evidence - Latin American Thoracic Society.
García G; Bergna M; Vásquez JC; Cano Salas MC; Miguel JL; Celis Preciado C; Acuña Izcaray A; Barros Monge M; García Batista N; Zabert I; Mayorga JL; Casanova Mendoza R; Gutierrez M; Montero Arias MF; Urtecho Perez L; Antúnez M; Williams Derby V; Villatoro Azméquita A; Motiño L; De Oliveira MA; Rey Sanchez D; Arroyo M; Rodriguez M
ERJ Open Res; 2021 Jan; 7(1):. PubMed ID: 33532459
[TBL] [Abstract][Full Text] [Related]
19. The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment.
Huang WC; Fu PK; Chan MC; Chin CS; Huang WN; Lai KL; Wang JL; Hung WT; Wu YD; Hsieh CW; Wu MF; Chen YH; Hsu JY
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33670157
[TBL] [Abstract][Full Text] [Related]
20. Biologics in asthma management - Are we out of breath yet?
Struß N; Hohlfeld JM
Allergol Select; 2021; 5():96-102. PubMed ID: 33615123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
